trending Market Intelligence /marketintelligence/en/news-insights/trending/Py0bLWbpsuQjl_I2-v5Yug2 content esgSubNav
In This List

Matinas raising $30M from common stock offering to fund pipeline development

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Matinas raising $30M from common stock offering to fund pipeline development

Matinas BioPharma Holdings Inc. priced an offering of 27,272,727 shares at $1.10 apiece to raise $30.0 million in gross proceeds.

BTIG LLC, the sole book-running manager for the offering, has an option to buy up to an additional 4,090,909 of the biopharmaceutical company's shares.

Bedminster, N.J.-based Matinas BioPharma said it plans to close the offering on or around March 19.

Net proceeds from the offering will be used to fund ongoing development activities of Matinas' potential drugs, including MAT9001 in the treatment of heart and metabolic conditions, and its lipid nano-crystal platform delivery technology, which can make medicines safer, more tolerable, less toxic and orally bioavailable.

In addition, the proceeds will be used to fund working capital and other general corporate purposes.